日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist

双内皮素受体拮抗剂马西替坦对多药耐药卵巢肿瘤的抗血管治疗

Sun-Jin Kim, Jang Seong Kim, Seung Wook Kim, Seok Joong Yun, Junqin He, Emily Brantley, Dominic Fan, Panja Strickner, François Lehembre, Urs Regenass, Isaiah J Fidler

Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer

马西替坦 (ACT-064992) 是一种组织靶向内皮素受体拮抗剂,可通过调节转移性人类卵巢癌原位模型中的生存途径来增强紫杉醇的治疗效果

Sun-Jin Kim, Jang Seong Kim, Seung Wook Kim, Emily Brantley, Seok Joong Yun, Junqin He, Marva Maya, Fahao Zhang, Qiuyu Wu, François Lehembre, Urs Regenass, Isaiah J Fidler